BTG Pactual Asset Management US LLC Makes New Investment in Becton, Dickinson and Company $BDX

BTG Pactual Asset Management US LLC bought a new stake in Becton, Dickinson and Company (NYSE:BDX) during the 2nd quarter, according to its most recent filing with the Securities and Exchange Commission. The firm bought 2,864 shares of the medical instruments supplier’s stock, valued at approximately $433,000.

A number of other institutional investors have also modified their holdings of BDX. Imprint Wealth LLC purchased a new position in Becton, Dickinson and Company during the 3rd quarter worth $25,000. SHP Wealth Management purchased a new stake in shares of Becton, Dickinson and Company in the fourth quarter valued at about $26,000. Meeder Asset Management Inc. increased its stake in shares of Becton, Dickinson and Company by 152.2% during the first quarter. Meeder Asset Management Inc. now owns 169 shares of the medical instruments supplier’s stock worth $27,000 after acquiring an additional 102 shares during the period. Main Street Group LTD purchased a new position in Becton, Dickinson and Company during the first quarter worth about $29,000. Finally, Bell Investment Advisors Inc acquired a new stake in Becton, Dickinson and Company in the second quarter valued at about $29,000. Institutional investors and hedge funds own 86.97% of the company’s stock.

Analyst Upgrades and Downgrades

A number of equities research analysts have weighed in on BDX shares. Stifel Nicolaus set a $195.00 price objective on Becton, Dickinson and Company in a report on Friday, August 7th. Wells Fargo & Company raised their price target on Becton, Dickinson and Company from $161.00 to $170.00 and gave the company an “equal weight” rating in a report on Friday, August 7th. Evercore set a $180.00 price target on Becton, Dickinson and Company in a research note on Monday, July 6th. Bank of America upped their price objective on Becton, Dickinson and Company from $185.00 to $200.00 and gave the stock a “neutral” rating in a report on Monday. Finally, Citigroup reissued a “buy” rating on shares of Becton, Dickinson and Company in a report on Thursday, August 13th. Eight research analysts have rated the stock with a Buy rating, eight have issued a Hold rating and one has assigned a Sell rating to the company’s stock. According to MarketBeat, Becton, Dickinson and Company currently has an average rating of “Hold” and a consensus price target of $187.67.

Becton, Dickinson and Company Price Performance

Shares of NYSE:BDX opened at $188.13 on Tuesday. The business’s 50 day simple moving average is $167.10 and its 200-day simple moving average is $160.32. The firm has a market capitalization of $51.84 billion, a price-to-earnings ratio of 56.67, a price-to-earnings-growth ratio of 13.36 and a beta of 0.19. The company has a debt-to-equity ratio of 0.55, a current ratio of 0.87 and a quick ratio of 0.51. Becton, Dickinson and Company has a 12 month low of $127.59 and a 12 month high of $193.07.

Becton, Dickinson and Company (NYSE:BDX) last released its quarterly earnings data on Thursday, August 6th. The medical instruments supplier reported $3.23 earnings per share for the quarter, beating the consensus estimate of $3.14 by $0.09. The firm had revenue of $4.98 billion during the quarter, compared to the consensus estimate of $4.89 billion. Becton, Dickinson and Company had a return on equity of 14.79% and a net margin of 4.52%.Becton, Dickinson and Company’s quarterly revenue was up 5.4% on a year-over-year basis. During the same period last year, the business posted $3.68 EPS. Becton, Dickinson and Company has set its FY 2026 guidance at 12.620-12.720 EPS. As a group, equities analysts forecast that Becton, Dickinson and Company will post 12.67 earnings per share for the current fiscal year.

Becton, Dickinson and Company Announces Dividend

The company also recently declared a quarterly dividend, which will be paid on Wednesday, September 30th. Stockholders of record on Wednesday, September 9th will be paid a dividend of $1.05 per share. This represents a $4.20 annualized dividend and a dividend yield of 2.2%. The ex-dividend date of this dividend is Wednesday, September 9th. Becton, Dickinson and Company’s payout ratio is 126.51%.

Insider Buying and Selling at Becton, Dickinson and Company

In other Becton, Dickinson and Company news, EVP Michael Feld sold 165 shares of the firm’s stock in a transaction dated Wednesday, August 26th. The shares were sold at an average price of $188.49, for a total transaction of $31,100.85. Following the completion of the transaction, the executive vice president directly owned 19,720 shares in the company, valued at approximately $3,717,022.80. This trade represents a 0.83% decrease in their position. The transaction was disclosed in a legal filing with the SEC, which can be accessed through this link. The transaction was executed under a pre-arranged Rule 10b5-1 trading plan. Also, CEO Thomas E. Polen, Jr. sold 4,152 shares of the company’s stock in a transaction dated Thursday, August 13th. The shares were sold at an average price of $185.00, for a total transaction of $768,120.00. Following the completion of the sale, the chief executive officer directly owned 110,163 shares in the company, valued at $20,380,155. This trade represents a 3.63% decrease in their position. The SEC filing for this sale provides additional information. The transaction was executed under a pre-arranged Rule 10b5-1 trading plan. Insiders have sold 9,105 shares of company stock valued at $1,590,208 over the last 90 days. 0.40% of the stock is currently owned by corporate insiders.

Becton, Dickinson and Company Profile

Becton, Dickinson and Company (BDX) is a global medical technology company that develops, manufactures and sells a broad range of medical devices, instrument systems and reagents. BD’s products are used by healthcare institutions, clinical laboratories, life science researchers and the pharmaceutical industry to enable safe, effective delivery of care, specimen collection and diagnostic testing. The company’s operations span multiple business areas focused on medical devices, life sciences research tools and interventional technologies.

BD’s product portfolio includes single-use medical devices such as syringes, needles, needlesafety and injection systems, infusion therapy and medication management solutions, as well as vascular access, urology and oncology devices acquired through its interventional business.